CREO vs. EKF, NCYT, MXCT, NIOX, FUM, ANCR, 4BB, KOO, FARN, and AGY
Should you be buying Creo Medical Group stock or one of its competitors? The main competitors of Creo Medical Group include EKF Diagnostics (EKF), Novacyt (NCYT), MaxCyte (MXCT), NIOX Group (NIOX), Futura Medical (FUM), Animalcare Group (ANCR), 4basebio (4BB), Kooth (KOO), Faron Pharmaceuticals Oy (FARN), and Allergy Therapeutics (AGY). These companies are all part of the "medical" sector.
EKF Diagnostics (LON:EKF) and Creo Medical Group (LON:CREO) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, media sentiment, profitability, dividends, risk, analyst recommendations and community ranking.
EKF Diagnostics received 221 more outperform votes than Creo Medical Group when rated by MarketBeat users. Likewise, 76.76% of users gave EKF Diagnostics an outperform vote while only 67.52% of users gave Creo Medical Group an outperform vote.
EKF Diagnostics has a net margin of 4.47% compared to EKF Diagnostics' net margin of -85.54%. Creo Medical Group's return on equity of 3.83% beat EKF Diagnostics' return on equity.
71.4% of EKF Diagnostics shares are owned by institutional investors. Comparatively, 45.1% of Creo Medical Group shares are owned by institutional investors. 5.1% of EKF Diagnostics shares are owned by company insiders. Comparatively, 20.7% of Creo Medical Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
In the previous week, Creo Medical Group had 2 more articles in the media than EKF Diagnostics. MarketBeat recorded 2 mentions for Creo Medical Group and 0 mentions for EKF Diagnostics. EKF Diagnostics' average media sentiment score of 1.50 beat Creo Medical Group's score of 0.00 indicating that Creo Medical Group is being referred to more favorably in the news media.
EKF Diagnostics has higher revenue and earnings than Creo Medical Group. Creo Medical Group is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks.
EKF Diagnostics has a beta of 0.56, suggesting that its stock price is 44% less volatile than the S&P 500. Comparatively, Creo Medical Group has a beta of 0.86, suggesting that its stock price is 14% less volatile than the S&P 500.
Summary
EKF Diagnostics beats Creo Medical Group on 10 of the 15 factors compared between the two stocks.
Get Creo Medical Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for CREO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CREO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Creo Medical Group Competitors List
Related Companies and Tools
